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Aims: The mechanisms underlying the selective degener-
ation of motor neurones in amyotrophic lateral sclerosis
(ALS) are poorly understood. The aim of this study was
to implement spatially resolved RNA sequencing in
human post mortem cortical tissue from an ALS patient
harbouring the C9orf72 hexanucleotide repeat expan-
sion to identify dysregulated transcripts that may
account for differential vulnerabilities of distinct (i) cell
types and (ii) brain regions in the pathogenesis of ALS.
Methods: Using spatial transcriptomics (ST) we analysed
the transcriptome of post mortem brain tissue, with spa-
tial resolution down to 100 lm. Validation of these find-
ings was then performed using BaseScope, an adapted, in
situ hybridization technique with single-transcript sin-
gle-cell-resolution, providing extensive regional and cell-
type specific confirmation of these dysregulated tran-
scripts. The validation cohort was then extended to
include multiple post mortem brain regions and spinal
cord tissue from an extended cohort of C9orf72, sporadic
ALS (sALS) and SOD1 ALS cases. Results: We identified
sixteen dysregulated transcripts of proteins that have
roles within six disease-related pathways. Furthermore,
these complementary molecular pathology techniques
converged to identify two spatially dysregulated tran-
scripts, GRM3 and USP47, that are commonly dysregu-
lated across sALS, SOD1 and C9orf72 cases alike.
Conclusions: This study presents the first description of
ST in human post mortem cortical tissue from an ALS
patient harbouring the C9orf72 hexanucleotide repeat
expansion. These data taken together highlight the
importance of preserving spatial resolution, facilitating
the identification of genes whose dysregulation may in
part underlie regional susceptibilities to ALS, crucially
highlighting potential therapeutic and diagnostic targets.
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Introduction
Genetics can influence the development of amyotrophic
lateral sclerosis (ALS), with both causative genes in
familial cases (fALS) and an increasing number of sus-
ceptibility genes. fALS cases make up approximately
10–20% of all cases of ALS and over a dozen causative
genes have been described [1,2]. The recently identified
intronic hexanucleotide repeat expansion in chromo-
some 9 open reading frame 72 (C9orf72) accounts for
40–50% of fALS [3,4]. Carrying and ubiquitously
*Correspondence: Jenna M. Gregory and Colin Smith, Centre for
Clinical Brain Sciences, University of Edinburgh, Chancellor’s
Building, Edinburgh EH16 4SB, UK. Tel: +44 0131 465 9519;
E-mail: jgregor2@ed.ac.uk and col.smith@ed.ac.uk
© 2020 The Authors. Neuropathology and Applied Neurobiology published by John Wiley & Sons Ltd
on behalf of British Neuropathological Society..
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and
reproduction in any medium, provided the original work is properly cited.
1
Neuropathology and Applied Neurobiology (2020) doi: 10.1111/nan.12597
expressing this repeat expansion is thought to result in
neurotoxicity and cell death contributing to the clinical
manifestations of ALS through three putative mecha-
nisms: (i) repeat-associated non-AUG (RAN)-translation
of the hexanucleotide repeat, resulting in five highly
aggregation-prone dipeptide repeat proteins, whose
pathological accumulation is thought to cause pro-
teotoxic stress, cytotoxicity and may lead to the seques-
tration of other aggregation-prone proteins [5], (ii)
pathological formation of RNA foci, potentially seques-
tering functional RNA transcripts and RNA/DNA-bind-
ing proteins preventing their normal function [6] and
(iii) loss of normal C9orf72 protein function due to
haploinsufficiency resulting from the repeat expansion
inhibiting normal protein production [7]. However,
there is considerable heterogeneity in the penetrance
and clinical manifestations of the C9orf72 repeat
expansion mutation, where patients who carry the
same mutation present with diverse symptoms that
span an ALS-frontotemporal dementia (FTD) spectrum
[8]. This considerable clinical heterogeneity presents a
substantial diagnostic challenge and makes stratifica-
tion of ALS patients in clinical trials very difficult. How-
ever, despite this clinical heterogeneity there are shared
pathological pathways in ALS pathogenesis [9].
TDP-43 is an RNA/DNA-binding protein involved in
transcriptional regulation and is found at post mortem
in the majority of ALS cases to be misfolded and accu-
mulated as cytoplasmic aggregates [10]. The pathologi-
cal misfolding of TDP-43 is thought to contribute to
neurotoxicity through two major pathways: (i) gain of
function, due to the presence of toxic aggregates in the
cytoplasm that have the ability to sequester other
aggregation-prone proteins and impair the balance of
proteostasis in the cell and (ii) loss of function, whereby
the normally nuclear TDP-43 is sequestered in cyto-
plasmic aggregates and is no longer able to participate
in transcriptional regulation [9]. Clearly, given the
common neuropathological finding of TDP-43 aggre-
gates in central nervous system (CNS) tissue at post
mortem in a majority of ALS cases, transcriptional dys-
regulation resulting from TDP-43 loss of function is an
important mechanism warranting further investigation.
Importantly, once thought of as purely a disorder of
motor neurones, ALS is now recognized as showing a
complex interplay between neurones and glia [11].
Indeed, glial TDP-43 inclusions are seen in cases of
ALS and FTD, and there is evidence supporting active
neuroanatomical propagation of molecular processes
[12].
RNA sequencing allows transcriptional information
to be analysed from ALS patients and compared with
control tissue to highlight key pathways involved in
the pathological disease process. Currently, RNA
sequencing studies use whole-tissue homogenates of
specific brain regions and cannot provide in situ infor-
mation at a cellular level regarding the complex rela-
tionship between different cell types due to the lack of
spatial resolution. A recently developed technique,
called spatial transcriptomics (ST), has been developed
that modifies RNA sequencing methodology to allow
interrogation of the entire transcriptome while retain-
ing in situ spatial information [13]. This technique has
been successfully implemented in ALS mouse models
and human spinal cord tissue [14].
Post mortem CNS tissue is subject to high levels of
autolysis and ALS CNS tissue is particularly vulnerable
to these post mortem changes as patients often die in an
acidotic state due to agonal respiratory failure. We
therefore chose to examine an area of the brain, the
cerebellum, that is better preserved at post mortem com-
pared to other brain regions [15] and only selected tis-
sue with an RNA integrity number (RIN) of greater
than 6. The additional benefit of examining the cerebel-
lum is that, in ALS patients carrying the C9orf72 hex-
anucleotide repeat, there is a high burden of protein
misfolding without the corresponding cell death that is
seen in other brain areas [16]. This is particularly use-
ful when examining transcriptional dysregulation
because in brain areas with substantial cell death, for
example in the motor cortex, there will be a number of
transcripts whose dysregulation is simply related to cell
death and is not related to active disease processes. Our
aim in this study is therefore to initially examine the
cerebellum to circumvent this ‘dying-cell artefact’ and
then validate any potential candidate transcripts in
other brain regions using a complementary technique,
BaseScope. By assessing only the granule cell layer of
the cerebellum (substantial pathology with no associ-
ated cell death), this approach enables us to focus on
transcripts associated with active disease rather than
artefacts of dying tissue.
This is, to our knowledge, the first known application
of this technology to deeply phenotyped human
C9orf72 ALS cortical tissue with a unique approach to
circumvent dying-cell artefact. Furthermore, due to
© 2020 The Authors. Neuropathology and Applied Neurobiology published by John Wiley & Sons Ltd
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limitations in the spatial resolution of ST (100 lm), we
implemented, in parallel, a complementary technique
called BaseScope, as a targeted approach with single-
transcript, single-cell resolution [17]. Taken together
these techniques have allowed us to interrogate the
previously unexplored, spatial transcriptome of human
post mortem ALS CNS tissue.
The aim of this study was to detect and spatially
resolve transcriptional differences between brain
regions and their composite cell types in ALS patient
neural tissue compared to control tissue, to identify
underlying differential cell vulnerabilities to the disease
process in ALS, ultimately to inform therapeutic target
selection and biomarker development in this field.
Experimental procedures
Case and tissue selection
All clinical data were collected as part of the Scottish
Motor Neurone Disease register (ethics approval from
Scotland A Research Ethics Committee 10/MRE00/78
and 15/SS/0216) and all patients consented to the use
of their data during life. All post mortem tissue was col-
lected via the MRC Edinburgh Brain Bank (East of Scot-
land Research Ethics Services [EoSRES] LR/16/ES/
0084). Use of human tissue for post mortem studies has
been reviewed and approved by the Edinburgh Brain
Bank ethics committee and the Academic and Clinical
Central Office for Research and Development (ACCORD)
medical research ethics committee (AMREC). Cases had
all undergone whole genome sequencing and repeat-
prime PCR (for C9orf72 hexanucleotide repeat expan-
sion) to identify genetic diagnoses.
Control cases were age-matched and had no neuro-
logical disease during life and no significant neu-
ropathology identified at post mortem examination.
Spatial transcriptomics
For a detailed explanation of how the spatial transcrip-







The RNA integrity number (RIN) of the tissues used
was ALS: 6.2 and Control: 6.8. A block of brain tissue
was cut to an appropriate size, approximately 5–
7 mm2 and sections were cut on a cryostat set to
20°C at 10 lm thickness on to the commercially
available library preparation ST slides within the pre-
specified areas containing the mRNA probes (six areas
per slide). One area was left blank as a negative con-
trol. Once cut, slides and sectioned tissue were stored
at 80°C. All subsequent work was carried out inside
a clean laminar flow hood. The slide was heated for
1 min at 37°C. Nine hundred microlitres of freshly
diluted 4% paraformaldehyde was added to the surface
of the slide ensuring all tissue was covered and incu-
bated at room temperature for 10 min. The slide was
then washed by dipping in to 19 PBS (phosphate buf-
fered saline) five times followed by incubation in
500 ll isopropanol for 1 min and the slide was then
air-dried. Haematoxylin and eosin (H&E) staining was
performed by firstly incubating sections in 500 ll Har-
ris haematoxylin (ThermoFisher) for 4 min and washed
by dipping 10 times in RNAase/DNAase free water and
1 dip in acid alcohol (1 % HCl in 70 % ethanol) fol-
lowed by 10 further dips in RNAase/DNAase free
water. Sections were then incubated in 500 ll of blu-
ing buffer (Dako) for 30 sec followed by dipping 10
times in RNAase/DNAase free water. Sections were
then incubated in 500 ll of Eosin Y (ThermoFisher) for
4 min followed by dipping 10 times in RNAase/DNAase
free water. Slides were then air-dried and incubated at
37°C for 5 min and mounted with a coverslip using
100 ll of 85% glycerol. The slide was then imaged at
409 magnification. The remainder of the procedure
was done as previously reported [13]. In brief, follow-
ing removal of the coverslip, prepermeabilization (5-
min incubation) and permeabilization (10-min incuba-
tion) was performed using pepsin and collagenase, fol-
lowed by cDNA synthesis and probe cleavage on the
slide. Samples collected following probe cleavage were
then processed as per library preparation protocol pub-
lished previously [13] to prepare the probe-mRNA con-
struct for sequencing (involving the addition of the
Illumina adapter (read 2) and the third unique molecu-
lar identifier (UMI), the array ID). The finished libraries
then underwent quality control by assessing integrity
and concentration by bioanalyser analysis (high sensi-
tivity chip) and qubit analysis. Following this, four
libraries (2 9 ALS and 2 9 control) were submitted to
© 2020 The Authors. Neuropathology and Applied Neurobiology published by John Wiley & Sons Ltd
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Edinburgh Genomics for 75 paired end sequencing over
1 lane of a flow cell as 1 pooled library on the HiSeq
4000 platform. Sequences were analysed as detailed in
the ST pipeline ([18]; an automated pipeline for spatial
mapping of unique transcripts Oxford BioInformatics
10.1093/bioinformatics/btx211). In brief, fastq files for
paired reads (read 1 and read 2) were decoupled using
their unique well IDs. Analysis firstly involved quality
trimming by removing reads with low quality bases
and low quality UMIs, removing artefacts and checking
AT and GC content. The reads were then mapped to
the human reference genome version 89 using STAR
software, demultiplexed (removing duplicate reads)
using Taggd software and then individual reads were
annotated using htseq-count and group annotated by
barcode (spot position), gene and genomic location to
obtain the read count [18]. The final output included
the gene name, read count and spot position in a for-
mat that was directly uploaded to the ST viewer soft-
ware [18] for integration with the two high-resolution
images (i) H&E (tissue morphology) and (ii) Cy3 spots
(location of transcripts) for spatial analysis. Following
this, spatial analysis was performed using the ST
viewer software according to the user manual [18].
Spots underlying the granule cell layer were selected
based on cell morphology determined by H&E image
(spots highlighted by white circles in Figure 1B), spots
on the edge of each region were excluded from the
analysis, to reduce bias. Analysis was performed in ST
viewer comparing the most differentially expressed
transcripts based on predetermined spot selections. NB:
we only selected spots directly underlying tissue and
QC data are presented in Table S2.
Immunohistochemistry
p62 staining was performed on serial sections of frozen
brain tissue cut at the same time, same temperature
and same thickness as ST sections. Sections were
placed in a slide holder in running tap water to remove
OCT and washed in Tris buffered saline (TBS) for 5 min
followed by incubation with mouse-anti-p62 primary
antibody (BDbio-610833 150 ug LCK ligand) at a 1 in
1000 dilution in TBS overnight at room temperature.
Antibody detection was then performed using Novolink
max polymer detection kit. A 5-min wash with TBS
was followed by a post primary blocking step for
30 min at room temperature, followed by a 5-min
wash with TBS and incubation with Novolink polymer
for 30 min at room temperature. A TBS wash for
5 min was then followed by incubation with 3, 30
diaminobenzidine tetrahydrochloride (DAB) (50 l chro-
mogen + 1 ml DAB substrate buffer) for 5 min followed
by washing in running water for a further 2 min. The
sections were then counterstained with Harris haema-
toxylin for 1 min followed by dipping in lithium car-
bonate for 30 sec, then a dip in each of 70% ethanol
and xylene and mounted with a 24 9 50 mm cover-
slip using two drops of VectaMount mounting medium.
Sections were then imaged at 20 9 magnification on a
NanoZoomer.
BaseScope
For a detailed explanation of how the BaseScope tech-
nology works please see the manufacturer’s website:
https://acdbio.com/science/how-it-works.
Brain tissue was taken at post mortem from standard-
ized Brodmann areas (BA) and fixed in 10% formalin
for a minimum of 24 h. Tissue was dehydrated in an
ascending alcohol series (70–100%) followed by three
successive 4-h washes in xylene. Three successive 5-h
paraffin wax embedding stages were performed followed
by cooling and sectioning of the FFPE (formalin-fixed
paraffin embedded) tissue on a Leica microtome in
4 lm sections on to a superfrost microscope slide.
BaseScope reagents (Advanced Cell Diagnostics) were
used as per manufacturer’s guidelines according to the
original protocol [17]. In brief, following deparafiniza-
tion, tissue sections were incubated with hydrogen per-
oxide for 10 min at room temperature and target
antigen retrieval was performed by submerging slides
in BaseScope 1X target retrieval reagent at 99°C in a
Braun Multiquick FS 20 steamer for 15 min. The tissue
was then permeabilized using BaseScope protease III at
40°C for 30 min. Probe hybridization was then per-
formed by incubating the slides with four drops of cus-
tom designed BaseScope probe, negative control probe
(DapB) or positive control (PPIB) probe for 2 h at 40°C.
Following successive probe amplification steps, tran-
scripts were detected using the BaseScope RED detec-
tion kit and slides were counterstained using
haematoxylin and lithium carbonate. The slides were
then cleared in xylene and mounted with a
24 9 50 mm coverslip using two drops of VectaMount
mounting medium. Sections were then imaged at
© 2020 The Authors. Neuropathology and Applied Neurobiology published by John Wiley & Sons Ltd
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Figure 1. Spatial transcriptomics identifies 16 candidate transcripts with dysregulated expression in cerebellum of ALS C9orf72 patient.
(A) Left panels: haematoxylin and eosin (H&E) stained sections of cerebellum (above: control tissue and below: C9orf72 - ALS tissue) with
Cy3 hybridization highlighting the spatial transcriptomics localization spots (pseudocoloured white) underlying the tissue. Right panels:
serial sections immuno-stained with anti-p62 antibody highlighting p62-positive aggregates within the granule cell layer of the
cerebellum of C9orf72 - ALS tissue, but not control tissue. Scale: white dot diameter = 100 µm diameter. (B) H&E stained sections of
cerebellum of the two control sections and one C9orf72 - ALS section used in the ST analysis. Spots highlighted with white rings are the
spots selected for analysis of the granule cell layer. Scale: dot diameter = 100 µm diameter. (C) BaseScope identification of single
transcripts (1 red dot = 1 single transcript) within the granule cells of the cerebellum, counterstained with haematoxylin. Top panels:
control tissue, bottom panels: C9orf72 - ALS tissue (red arrows indicated single mRNA transcripts). Scale bar = 20 µm. (D) Sections of
cerebellum counterstained with haematoxylin showing cell-type specific expression (1 single red dot = 1 single transcript) of GRM3,
identified by BaseScope in the interneurons of the cerebellum, with increased expression in the interneurons (black arrows) of the
C9orf72 - ALS case compared to controls. Scale bar = 50 µm. (E) Sections of cerebellum counterstained with haematoxylin showing cell-
type specific expression of YWHAE, identified by BaseScope in the interneurons (red arrows) and Purkinje cells (black arrows) of the
cerebellum, with increased expression in the interneurons of the C9orf72 - ALS case compared to increased expression within the
Purkinje cells in the controls. Scale bar = 50 µm.
© 2020 The Authors. Neuropathology and Applied Neurobiology published by John Wiley & Sons Ltd
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20 9 magnification on a NanoZoomer slide scanner
and the number of transcripts per cell was quantified
by two independent pathologists.
Statistics
Differential expression was defined as >3-fold difference
in expression (median number of transcripts identified
per feature) between ALS and control tissue, but not
between technical replicates of control tissue. Any tran-
scripts where the overall read count was zero were
excluded, to limit zero-inflation, as it is not possible to
say whether this was because (i) there was no expres-
sion of that gene in that selection, or (ii) whether there
was insufficient coverage to detect it or (iii) whether
there has been degradation of the transcript. Therefore,
transcripts were included as potential hits if they (i)
reached statistical significance (compared to control
expression), (ii) had a median number of transcripts
per feature not equal to zero and (iii) had a greater
than 3-fold difference between case and control expres-
sion. Due to the extensive nature of our planned vali-
dation cohort (multiple brain regions and multiple ALS
cases including sporadic ALS (sALS), SOD1 and addi-
tional C9orf72 cases), this strict filtering process was
performed to enable the greatest confidence in selecting
a manageable number of high-value candidate tran-
scripts. Median number of transcripts per feature was
calculated by the ST software as stated above, data
were not normally distributed and therefore signifi-
cance was calculated by nonparametric testing using
Mann-Whitney U test.
For BaseScope analysis, gene expression was calcu-
lated by counting the number of transcripts per cell in
three randomly generated fields of view (1 mm2) and
then averaged. This was done for each of the twelve
cases (three C9orf72 cases, three control cases, three
sALS cases and three SOD1 cases) and the mean and
standard deviation was plotted for each of the groups.
Therefore, each group (Control, C9orf72, sALS and
SOD1) plotted on the graph is the mean and standard
deviation of three fields of view in three individuals.
Differences in expression (number of dots/transcripts
per cell; measured by BaseScope) between ALS case
and control in Figure 1 were assessed by two-tailed
unpaired t-tests following log transformation (x’ = log
Figure 2. Spatial dysregulation of GRM3 and USP47 in
cerebellum of an extended cohort of ALS C9orf72 patients. (A–
Table summarizing the clinical data associated with the C9orf72
case selected for spatial transcriptomics evaluation.) Graphs
quantifying expression of transcripts (measured by BaseScope) in
three additional C9orf72 cases and three additional control cases,
demonstrating that only USP47 (A) and GRM3 (B) are
consistently dysregulated in all cases, whereas spatial differences
in YWHAE expression do not reach statistical significance (C).
Error bars indicate standard deviation.
© 2020 The Authors. Neuropathology and Applied Neurobiology published by John Wiley & Sons Ltd
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x + 1). Differences in expression in Figures 2–4 and
Figure S2 were analysed using 1-way ANOVA (follow-
ing log transformation), compared to control expression
using a Bonferroni post-test correction for multiple test-
ing.
Results
ST analysis identified 16 candidate transcripts with
spatially dysregulated expression
Spatial transcriptomics analysis was performed on fro-
zen sections of cerebellum from one ALS and one age-
and sex-matched control case (Figure 1A and B). A
summary of the clinical data of this case is included in
Table 1. Serial sections were stained for p62 to demon-
strate that there was evidence of substantial protein
aggregation in the granule cell layer of the cerebellum
of the ALS case, but not in the control case (Figure 1A;
right panel). Initially, as a quality control (QC) exercise
to test the ST analysis pipeline and software, to ensure
that the images and transcripts were correctly aligned
and that ST analysis can distinguish between different
regions of the cerebellum, two QC experiments were
performed. The first assessed four spatially conserved
transcripts, known to be differentially expressed in each
of the granule cell layer, molecular cell layer, Purkinje
cells and white matter, were analysed and visualized as
a heat map of expression. Spatial transcript expression
analysis in this way demonstrated accurate regional
specificity (Figure S1). The second QC experiment
involved simulation of a whole-tissue RNA sequencing
experiment and subsequent comparison of our data to
a previously published whole-tissue data set. A tran-
scriptomic analysis of post mortem whole-tissue from
the cerebellum of patients carrying the C9orf72 hex-
anucleotide repeat expansion was conducted previ-
ously, identifying 15 genes that were dysregulated
between C9orf72 tissue and control tissue [19]. Com-
parison of the entire section of our tissue, simulating a
whole-tissue experiment, revealed that five of the 15
dysregulated transcripts detected in this previous study
were replicated in our analysis (ALAS2, HSPH1,
DNAJB1, HSPA1A and HSPA1B; Table S1).
Following these QC experiments, ST analysis was
performed comparing control and ALS granule cell lay-
ers to identify candidate transcripts that may be differ-
entially expressed accounting for differential
vulnerabilities to disease. Only the spots underlying the
granule cell layer (spots selected with a white circle;
Figure 1B) were included in the analysis. The number
of expressed genes identified in each of the sections ran-
ged from 1123 in the ALS tissue and up to 2588 in
the control tissue (summary of QC data is presented in
Table S2). The number of genes identified was lower
than expected, however is in line with other transcrip-
tome analyses done in post mortem ALS CNS tissue
[14]. This has been hypothesized to be a result of post
mortem autolysis, which primarily affects 3’ and 5’
ends of the mRNA, affecting the 3’ poly-A tag, crucial
to the mRNA capture prior to sequencing.
Spatial analysis followed by the strict filtering process
resulted in the identification of 16 differentially
expressed candidate transcripts ([13] with a higher
expression in ALS and 3 with a lower expression) in
the granule cell layer of post mortem ALS patient cere-
bellum (Table 2). Gene ontology (GO) analysis was per-
formed using pantherdb.org to identify common disease
pathways between the identified transcripts. This analy-
sis identified six prominent pathways: (i) proteostasis,
(ii) RNA/DNA-binding proteins, (iii) mitochondrial
metabolism, (iv) extracellular matrix, (v) excitotoxicity
and (vi) apoptosis.
BaseScope analysis validated eight candidate
transcripts and demonstrated highly specific spatially
dysregulated expression
Given the limitations, primarily in coverage, of ST in
our tissue we sought to validate the ST data using a
complementary technique, BaseScope, which has high
sensitivity and specificity for detection of transcripts on
a single-cell level in histological sections. Using this
technique, we assessed whether any of the sixteen tran-
scripts identified by ST were dysregulated in the same
case and control tissues as those used in the ST experi-
ment. A summary of the clinical data of all cases used
in for BaseScope validation is included in Table 3.
BaseScope analysis showed independent evidence of dif-
ferential expression for eight of the sixteen transcripts
(USP47, C5orf63, COL27A1, CELF1, MTRNR2, UBR7,
GRM3 and YWHAE; Figure 1C–E). Differential expres-
sion was not confirmed for the remaining eight tran-
scripts (Figure S2). Furthermore, the added value of
retaining spatial resolution was clearly highlighted by
the identification of two transcripts (GRM3 and
© 2020 The Authors. Neuropathology and Applied Neurobiology published by John Wiley & Sons Ltd
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YWHAE), whose expression was highly specifically dys-
regulated in C9orf72 cerebellum compared to control
cerebellum (Figure 1D and E). The expression of GRM3
is restricted to the interneurones of the granule cell
layer and is markedly increased in ALS granule cell
interneurones compared to control interneurones in
this layer (Figures 1D and 2B). The expression of
YWHAE is also spatially dysregulated. Its expression is
extensive within the cerebellum, however in control tis-
sue it is predominantly expressed in the granule cells
and the Purkinje cells, whereas in the ALS C9orf72
case its expression is strikingly redistributed from the
Purkinje cells to the interneurons of the granule cell
layer (Figure 1E). It is highly unlikely that these tran-
scriptional variations would have been identified using
a whole-tissue approach or indeed without the reten-
tion of spatial resolution.
Spatial dysregulation of GRM3 and USP47 in
cerebellum of an extended cohort of ALS C9orf72
patients
Due to cost of the existing ST technologies we had
assessed only a single C9orf72 case against a control
case, but we sought to validate our observations across
an increased number of C9orf72 cases by using BaseS-
cope. We validated the eight candidate transcripts
across an additional three C9orf72 cases with an addi-
tional three appropriately matched control cases. This
analysis revealed that there were two candidate tran-
scripts whose expression was consistently dysregulated
in the cerebellum of all three C9orf72 cases compared
to the controls: USP47 (Figure 2A) and GRM3 (Fig-
ure 2B). The mean expression of USP47 in the granule
cells of the cerebellum of C9orf72 patients was statisti-
cally significantly higher than that of control cases
(P = 0.005; t = 5.459; df = 4). Furthermore, expres-
sion of GRM3 in the cerebellar interneurones of ALS
C9orf72 cases was found to be over three times that of
control interneurones (P = 0.0204; t = 3.724; df = 4).
However, when the expression of YWHAE was
examined across an extended cohort of C9orf72 and
control patients, the difference between C9orf72
patients and control cases did not reach statistical sig-
nificance (Figure 2C).
Extended CNS analysis reveals spatial dysregulation
of GRM3 and USP47 in the cortex of diverse cohort
of ALS patients
Given the consistent validation of GRM3 and USP47
in an extended cohort of ALS C9orf72 patients with
two independent techniques (ST and BaseScope) we
next sought to extend our transcriptional analysis of
these two transcripts to additional brain regions and
to other cases of ALS including three cases of SOD1-
ALS and three cases of sALS compared to the three
C9orf72 cases and three controls. We assessed expres-
sion in the spinal cord, motor cortex, prefrontal cortex
and cerebellum of all twelve cases (Figure 3). There
was no expression of GRM3 in the spinal cord of any
of the cases (neither control nor ALS; Figure 3A).
However, whilst the transcriptional dysregulation
observed in the interneurons of the granule cell layer
of the cerebellum was restricted to C9orf72 cases, dys-
regulation of GRM3 across the cerebral cortex was a
phenomenon observed in all ALS cases (Figure 3A).
Expression of GRM3 in the motor cortex and pre-
frontal cortex was statistically significantly lower in
the C9orf72, sALS and SOD1 cases compared to con-
trols (Figure 3B), despite showing no significant differ-
ence in positive and negative control genes
(Figure S3). The expression of USP47 was also found
to be highly spatially dysregulated. Whilst the tran-
scriptional dysregulation observed in the granule cells
of the cerebellum was restricted to C9orf72 cases, dys-
regulation of USP47 across the cerebral cortex and
spinal cord was observed in all ALS cases (Figure 4A).
Expression of USP47 in the spinal cord, motor cortex
and prefrontal cortex was statistically significantly
lower in the C9orf72, sALS and SOD1 cases compared
to controls (Figure 4B).
Figure 3. Expression of GRM3 is downregulated globally in the cortex of ALS cases. (A) Representative images showing BaseScope
identification of single transcripts (1 red dot = 1 single transcript) within the cerebellum, spinal cord, motor cortex and prefrontal cortex
of brains of control, C9orf72, sALS and SOD1 patients. Images demonstrate localization of transcripts of GRM3 within the interneurons of
the cerebellum (white arrows) and global cortical downregulation of GRM3 in ALS cases compared to control cases. There is no
expression of GRM3 evident in the spinal cord of controls or ALS cases. Sections are counterstained with haematoxylin. (B) Graph
quantifying expression of GRM3 transcripts imaged in A in three control cases, three C9orf72 cases, three sALS cases and three SOD1
cases. Error bars indicate standard deviation.
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Discussion
Spatial transcriptomics is a powerful tool in the analy-
sis of (i) spatially heterogeneous tissues like the brain
and (ii) spatially heterogeneous diseases, like ALS. Our
ST analysis identified sixteen candidate dysregulated
transcripts from six relevant disease-related pathways.
Furthermore, the dysregulation of two of these tran-
scripts, GRM3 and USP47, was confirmed in an exten-
sive cohort of ALS patients, including three sALS cases
and three SOD1 ALS cases (all harbouring the p.I114T
Scottish founder mutation) in addition to three C9orf72
ALS cases, all compared to three control cases, using a
complementary technique, BaseScope.
GRM3 as a potential therapeutic target in ALS
Data in this study demonstrate that gene expression of
GRM3 is consistently lower in the prefrontal and motor
cortex in C9orf72 repeat expansion, mutant SOD1 and
sALS compared to controls. Furthermore, our data indi-
cate divergence of GRM3 expression between ALS sub-
types, where specifically GRM3 expression is higher in
interneurones in the granule cell layer of the cerebel-
lum in C9orf72 repeat expansion patients.
The GRM3 gene encodes mGlu3, a metabotropic glu-
tamate receptor known to modulate glutamate neuro-
transmission in the central nervous system. Data
obtained from control tissue by this study are consis-
tent with previous descriptions of the mGlu3 receptor
in human tissue; GRM3 is expressed in neurons within
the cerebral cortex, interneurons/Golgi cells in the cere-
bellum, but not in spinal cord neurons (reviewed in
[20]). Neuronal mGlu3 receptor expression is largely
found at presynaptic terminals, though at extrasynaptic
sites not associated with active synaptic zones. This
appears to be inherently related to the physiological
role of mGlu3 receptors, where activation by extrasy-
naptic glutamate overspill negatively regulates presy-
naptic vesicular release of glutamate by modulation of
presynaptic ion channel activity through G-protein sig-
nalling cascades [21–24]. The inhibition or decreased
expression of mGlu3 receptors is therefore consistent
with an increased glutamate transmission and excito-
toxic scenarios [25,26]. mGlu3 receptors are also
expressed in astrocytes and activation via synaptic glu-
tamate or mGlu3 agonists generate the release of neu-
roprotective neurotrophic factors in a rodent mutant
SOD1 ALS model [26]. Of note, the reduction of mGlu3
receptor expression in the prefrontal cortex is more
commonly associated with neuropsychiatric diseases
including schizophrenia and bipolar disorder [27,28].
These studies suggest there may be shared mechanistic
features between schizophrenia and ALS [29]. In this
regard, a common convergence of reduced mGlu3
receptors in ALS and neuropsychiatric disease is poten-
tially highlighted by the fact the mGlu3 receptor knock
out mouse was initially generated to understand neu-
ropsychiatric disease, however, also displays locomotor
dysfunction [30,31]. The development of selective
pharmacology targeting mGlu3 receptors in
Table 1. Summary of clinical data for C9orf72 case used in the
spatial transcriptomics experiment
Age of onset 54
Age at death 62
Disease duration (months) 97
Sex Female
El Escorial 3
Site of onset Lower limb
Family history Brother had MND
Genetics C9orf72 hexanucleotide repeat
expansion identified by repeat
prime PCR, no other abnormalities
identified by whole genome
sequencing.
Cognitive assessment ECAS – Impaired (total ECAS
score = 102; ALS-specific
score = 76; impaired in executive
and fluency tasks, but not in
language tasks)
Summary of pathology Brain weight 1220 g
p62 in dentate gyrus, CA4 sector of
hippocampus and granule cells of
cerebellum
Ventral nerve root atrophy
throughout spinal cord
Table summarizing the clinical data associated with the C9orf72
case selected for spatial transcriptomics evaluation.
Figure 4. Expression of USP47 is downregulated globally in the CNS of ALS cases. (A) Representative images showing BaseScope
identification of single transcripts (1 red dot = 1 single transcript) within the cerebellum, spinal cord, motor cortex and prefrontal cortex
of brains of control, C9orf72, sALS and SOD1 patients. Images demonstrate localization of transcripts of USP47 within the interneurons
of the cerebellum (white arrows) and global cortical downregulation of USP47 in ALS cases compared to control cases. There is no
expression of USP47 evident in the spinal cord of controls or ALS cases. Sections are counterstained with haematoxylin. (B) Graph
quantifying expression of USP47 transcripts imaged in A in three control cases, three C9orf72 cases, three sALS cases and three SOD1
cases. Error bars indicate standard deviation
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neuropsychiatric disease may also therefore be relevant
to motor aspects of ALS.
USP47 and de-ubiquitinating proteins
As the granule cell layer in C9orf72 post mortem cere-
bellar tissue is subject to a high burden of protein mis-
folding [32], it is understandable that the pathway
common to many of the candidate transcripts is
proteostasis. The upregulation of proteostatic mecha-
nisms such as chaperone proteins and the ubiquitin-
proteasome system (UPS) to cope with the high levels
of protein misfolding may enable these cells to survive
despite a high burden of cytotoxic protein misfolding.
The UPS is a pathway whereby cells can target
unwanted or misfolded proteins for degradation by
covalently linking them with ubiquitin molecules. This
ubiquitin chain targets the client protein to the

















(n = 3) P-value Pathway Gene info
APP 3 <0.05 3 0.40 0.45 >0.05 Proteostasis Signalling molecule
NFIB 3 <0.05 3 0.38 0.37 >0.05 RNA/DNA-binding Nuclear factor
1 B-type
USP47 3 <0.05 3 0.22 0.46 >0.05 Proteostasis De-ubiquitinating
protein












ALG14 5 <0.05 5 0.03 0.04 >0.05 Proteostasis ER N-glycosylation
FAM155A 5 <0.05 5 0.11 0.09 >0.05 Excitotoxicity Calcium import
CELF1 5 <0.05 5 1.39 1.56 >0.05 RNA/DNA-binding CUGBP Elav-like
family
GRM3 5 <0.05 5 0.76 3.01 <0.05 Excitotoxicity Metabotropic
glutamate
receptor




MTRNR2 13 <0.05 23 0.03 0.04 >0.05 Anti-apoptotic Neuroprotective/
anti-apoptotic


















(n = 3) P-value Pathway Gene info
YWHAE 4 <0.05 1 7.59 6.57 >0.05 Proteostasis Chaperone 14-3-3 protein
epsilon




UBR7 3 <0.05 1 0.20 0.18 >0.05 Proteostasis Putative E3 ubiquitin-
protein ligase
Upper panel of table displays information regarding the 13 transcripts that are upregulated in C9orf72 ALS tissue compared to control tis-
sue following filtering analysis. Lower panel displays information regarding the 3 transcripts that are down regulated in ALS tissue com-
pared to control tissue following filtering analysis.
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proteasome, where the protein is degraded and the
ubiquitin molecules recycled. There is evidence to sug-
gest that mechanisms exist to prioritize the degradation
of certain proteins over others by increasing the num-
ber of ubiquitin molecules attached to the protein [33].
The ability to either (i) reverse the fate of these ubiqui-
tinated proteins, (ii) recycle ubiquitin molecules or (iii)
prioritize specific proteins for degradation, relies upon
the function of de-ubiquitinating proteins. USP47,
found to exhibit lower expression in the cortex of our
ALS cohort patients compared to controls, is one such
de-ubiquitinating protein. De-ubiquitinating proteins
can either fully remove a ubiquitin motif from a protein
to prevent degradation, or remove only a part of it, to
enable recycling of ubiquitin molecules and/or to allow
for the prioritization of certain proteins by removing
ubiquitin molecules from proteins with a less urgent
need for degradation [33].
Expression of USP47 was also found to be specifically
increased in the granule cell layer of the cerebellum of
patients with the C9orf72 hexanucleotide repeat expan-
sion compared to controls, but not in the cerebellum of
patients with other causes of ALS (sporadic or SOD1
mutation). The cerebellum of C9orf72 ALS patients is
also found to have a high burden of protein misfolding,
particularly in the granule cell layer, where expression
of USP47 is found to be the greatest. There are, how-
ever, no clinical manifestations associated with this
high burden of protein misfolding. This implies, that
whilst there is clearly an underlying pathology, the
cells are somehow able to cope without evidence of
neurotoxicity seen in other similarly affected areas,
such as the motor cortex. The finding that USP47 is
increased in these cells could be associated with an
increased capacity to recycle ubiquitin and prioritize
toxic proteins, like TDP-43, for degradation. Indeed, the
cells of the granule cell layer in C9orf72 patients,
whilst containing abundant p62 positive protein aggre-
gates, rarely exhibit TDP-43 aggregation [32]. TDP-43
aggregation is seen in other brain regions and has been
associated, through multiple neuropathological, in vitro
and in vivo studies, with neurotoxicity therein [9]. It is
therefore possible that increasing the expression of de-
ubiquitinating proteins, such as USP47, may be a
potential therapeutic strategy in ALS patients.
USP47 has also been shown to be directly involved
in promoting cell survival through an anti-apoptotic
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transducin repeats-containing protein (beta-TRCP;
[34]). The observation, therefore, that USP47 is upreg-
ulated in the cerebellum, where there is comparatively
substantially less cell death, may be unrelated to its
role in proteostasis, and may instead be related to its
protective interaction with beta-TRCP. Furthermore,
USP47 has been shown to play a crucial, regulatory
role in axonal growth during development [35], there-
fore its reduced expression in the cortex could be asso-
ciated with axonal dysfunction. Further mechanistic
studies are clearly warranted to probe these regional
differences further. However, de-ubiquitinating proteins
are important drug targets in the oncology field,
demonstrating good safety and efficacy profiles [33]. It
is therefore possible that de-ubiquitinating enzymes
(DUBs) could provide a potential therapeutic target in
ALS.
Retaining spatial resolution
Our experiments demonstrated specific spatial localiza-
tion of regionally distinct transcripts (Figure S1). Fur-
thermore, our simulated whole-tissue evaluation was
able to validate five out of fifteen previously identified
dysregulated transcripts, that were independently vali-
dated by qPCR, from a whole-tissue analysis of C9orf72
patient cerebellar tissue (Table S1; [36]). This implies
that spatial transcriptomics is not only able to detect
and replicate differences found in whole-tissue experi-
ments, it also has the added benefit of being able to
detect, more targeted, hypothesis driven and spatially
resolved questions as implemented in our study. Using
this approach, we were able to identify two spatially
dysregulated transcripts that have previously eluded
classical whole-tissue approaches.
Moreover, by firstly assessing cerebellar tissue, we
were able to overcome previously identified issues
regarding death and dying-cell artefact. In motor cortex
and/or spinal cord, many transcripts are identified that
may be a generic signature of dying cells, rather than
a reflection of underlying pathology that could be driv-
ing the disease. By initially examining cerebellar tissue,
we were able to analyse the transcriptome of cells that
clearly have cellular pathology, including cytoplasmic
protein inclusions, but are not undergoing cell death,
and then validate candidate transcripts in other brain
regions using a more targeted approach. Using this
approach, we were able to demonstrate differential
dysregulation of transcripts across distinct CNS regions,
that may account for differential susceptibilities to the
underlying disease process.
Study limitations
ST is a new technology that, to our knowledge, has
never been used to interrogate human post mortem
brain tissue. As with any novel technology there are
limitations that must be taken into account when
assessing the generated data. Post mortem brain tissue
is subject to particularly high levels of autolysis com-
pared to other tissues, which may compromise its RNA
integrity. This technique is best implemented as a non-
biased assessment of the spatial transcriptome. Clearly
with tissue demonstrating substantial RNA degrada-
tion, there could be a bias towards the identification of
more robust transcripts potentially skewing the data
set. However, given these limitations, we implemented
an extensive validation of potential hits using a much
larger sample size (including both technical and biolog-
ical replicates) and a technique that is not subject to
the same degradation bias, BaseScope, which (i) can
detect partially degraded mRNA and (ii) can be imple-
mented on FFPE tissue, with better mRNA preservation
compared to frozen tissue. New refinements in ST tech-
nology, such as sequential approaches and/or compila-
tion of larger aligned data sets, may further extend the
applications of this technology to the assessment of
human neurodegenerative conditions [14,37].
Conclusions
Taken together these data indicate that through main-
taining spatial resolution when assessing transcrip-
tional dysregulation, it is possible to identify genes
whose dysregulation may be contributing to the differ-
ential regional and cell-type specific susceptibility to dis-
ease and may shed light upon previously unidentified
pathways contributing to the pathogenesis of ALS.
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Table S2. Summary of QC data from spatial transcrip-
tomics sequencing. Table summarizing the QC data
from the spatial transcriptomics sequencing. CF1 and
CF2 refer to the control sections and ME2 refers to the
motor neurone disease section
Figure S1. Expression heat map shows localized expres-
sion of candidate transcripts demonstrating regional
specificity of ST.
Figure S2. Six transcripts identified as differentially
expressed by ST showed no difference when assessed by
BaseScope in the same ALS case and control.
Figure S3. Expression of positive (PPIB) and negative
(DapB) control probes across all cases shows no statisti-
cally significant difference in RNA quantity or quality
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